Syntara's SNT-4728 Shows Early Signal in Parkinson's Pathway

Syntara (ASX:SNT) reported interim Phase 2 data for SNT-4728, the first clinical evidence that its anti-inflammatory therapy hits a biological process tied to Parkinson's disease. The study targets isolated REM Sleep Behaviour Disorder (iRBD), a condition that carries high risk of progression to Parkinson's or related disorders.

The trial is the first interventional study in iRBD patients designed to directly target neuroinflammation, an increasingly recognised driver of neurodegenerative disease. After 12 weeks, 20 of 30 patients on SNT-4728 showed a reduction in brain inflammation within the putamen, a region central to Parkinson's movement symptoms. The reduction was statistically significant.

No treatment-related serious adverse events were reported. Professor Simon Lewis, Director of the Parkinson's Disease Research Clinic at Macquarie University and a principal investigator, called the results "notable." He said detecting measurable biological change after three months in a population that can take more than a decade to develop Parkinson's symptoms is encouraging.

The company expects full dataset release later in Q3 2026, including additional brain imaging, digital and biological biomarkers. Syntara has filed a new provisional patent application covering SNT-4728 in iRBD.

For investors, the interim analysis is an early step toward a first-in-class therapy aimed at slowing the disease process years before clinical diagnosis, not just treating symptoms. SNT-4728 remains one of several clinical catalysts expected from Syntara's pipeline in 2026.

Disclaimer: This content has been prepared as part of a partnership with Syntara Ltd and is intended for informational purposes only.